Shares of Endocyte, Inc. (NASDAQ:ECYT) are currently poised at -2.05% from the open today and are hovering around at $1.91. More than 3,726,720 shares have traded hands versus an average trading volume of 438.21K. At the current PPS, the market capiralization stands at $115.90M. The stock prices of Endocyte, Inc. (NASDAQ:ECYT) are currently trading at -53.98% below its 52 week high and -3.54% above its 52 week low.
Endocyte, Inc. (NASDAQ:ECYT) has been in the buzz for the right reasons. Recently, Endocyte, Inc. (NASDAQ:ECYT) announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held between June 02-06, 2017, in Chicago
Endocyte, Inc. (NASDAQ:ECYT) is all set to post its earnings on May 10/b. As per Zack’s analyst ratings, Endocyte, Inc. (NASDAQ:ECYT) has an average brokerage rating of 1.67. On a scale of 1-5, a rating of 1 or 2 would show a buy, and a score of 4 or 5 would indicate a sell call. A rating of 3 would suggest a hold on the stock. The consensus price on (NASDAQ:ECYT) is $6.5 with a high of $8 and a low of $5.
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.
The Exponential Moving Average is similar to a simple moving average however it utilizes a weighting cog that exponentially drops from the recent data point. The study of EMA compares the short term, intermediate term and long term EMAs. The respective EMAs tend to give bullish signals when hovering above trailing EMAs and below the latest price and vice versa. EMA alerts constitute crossovers i.e. the 5-day EMA crosses below/above the 20 day EMA and EMA convergences 5-day EMA comparable to 13 day EMA. The 5 day EMA 2.39 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 2.43 is also higher than the current trading price depicting a bearish trend overall.
The relative strength index (RSI) can be defined as a momentum oscillator that can compute measure the velocity and extent of stock price changes. Momentum is computed as the ratio of positive price variations to negative price changes. The RSI study compares the current Relative Strength Index against oversold (30), overbought (70) and neutral (50) conditions. Alerts will apprise you when shares recede from oversold/overbought marks or breakthrough neutral (50). The current RSI is 35.20 suggesting a bearish price action.
Though Endocyte, Inc. (NASDAQ:ECYT) represents an exciting growth story open to numerous attractive markets, it would be remarkable to see how it does for long-term investors.